News

Zacks Investment Research on MSN4d
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...
Pfizer’s HYMPAVZI Shows Superiority in Hemophilia A/B with Inhibitors in Phase 3 Study
On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...
Applied Clinical Trials Online5d
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
PharmExec5d
Pfizer’s Hympavzi Demonstartes Significantly Reduced Annualized Bleeding Rates in Hemophilia
Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...
Pharmabiz4d
Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors
Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...
Fierce Pharma5d
Pfizer's hemophilia drug Hympavzi notches phase 3 win as pharma eyes label expansion
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...